Top Management Presentation
Financial Results of FY2017 Q2 (April 1 – September 30, 2017)

from the beginning

Top Management Presentation Financial Results of FY2017 Q2 (April 1 - September 30, 2017)

Forward-Looking Statements

Agenda

FY2017 Q2 Financial Results

Overview of FY2017 Q2 Results

Revenue

Operating Profit

Special Items

Profit Attributable to Owners of the Company

Revenue: Major Business Units (incl. Forex Impact)

Revenue: Major Products in Japan

FY2017 Revised Consolidated Forecast

FY2017 Revised Consolidated Forecast

Major Management Topics

Direct Oral Anticoagulant (DOAC) Market

DOAC Market in Japan and Germany

Lixiana: Growth in Japan(1)

Lixiana: Growth in Japan(2)

Lixiana: Growth in Germany and South Korea

Major Management Topics [US Pain Business]

Changes in US Pain Business

DSI: Commitments in Pain Care

Three Pain Management Products in US

Major Management Topics [Japan Business]

VIMPAT: Additional Indication and Lift of Prescription Period Restriction

VIMPAT: New Options for Epilepsy Medication

CANALIA Combination Tablet: Launched in Sep. 2017

Expansion of Product Portfolio in Japan

Shareholder Returns

Shareholder Returns

R&D Update

Agenda

R&D Focus and Efficiency

R&D Focus and Efficiency

DS-8201 Update U3-1402 Update

DS-8201: P1 Study Part 2d Result

DS-8201: P1 Study Part 2d Patient Demographics

DS-8201: P1 Study Part 2d Efficacy (6.4mg/kg)

DS-8201: P1 Study Part 2d Efficacy

DS-8201: P1 Study Part 2d CT Imaging

DS-8201: Part 1 to Part 2 Safety Profile

DS-8201: P1 Study Safety - TEAE, any grade, >20%

DS-8201: P1 Study Part 2d Conclusions

DS-8201: Development Plan

U3-1402: Development Plan

New Projects Entered to Clinical Phase

DS-1205: AXL Inhibitor Summary

DS-1205: Results of Pharmacology Study

New Collaboration in Oncology

Maximize ADC Technology: Collaboration with Glycotope

Collaboration with MD Anderson Cancer Center

Target DS Compounds and Image of Collaboration

Oncology Future Data Disclosure

Esaxerenone/CS-3150 Update

Mineralocorticoid Receptor Related Hypertension and Diabetic Nephropathy

Esaxerenone/CS-3150: P3 Study

FY2017 Major R&D Milestone Events (1)

FY2017 Major R&D Milestone Events (2)

DS R&D Day 2017

Contact address regarding this material

Appendix

Major R&D Pipeline

DS-8201: HER2 Positive Breast Cancer Pivotal P2 Study (JP/US/EU)

DS-8201: HER2 Positive Gastric Cancer Pivotal P2 Study (JP/Asia)

DS-8201: P1b Nivolumab Combination Study (US/EU)

U3-1402: HER3 Positive Breast Cancer P1/2 Study (JP)

U3-1402: EGFRm NSCLC P1 Study (US)

DS-1205: FIH P1 Osimertinib Combination Study (US)

CS-3150: Diabetic Nephropathy P3 Study (ESAX-DN Study) (JP)

Abbreviations

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8

• Q&A 9

• Q&A 10